Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing ...

The large molecule injectable drugs market is anticipated to expand at a CAGR of ~9% during the forecast period. Key drivers ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

The global veterinary dermatology market, valued at US$18.59 billion in 2024, is forecasted to grow at a robust CAGR of 8.5%, ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including patient-reported outcomes (PRO) ...

The Global Cough Remedies Market is valued at approximately USD 7.83 billion in 2023 and is projected to grow with a steady CAGR of 3.9% over the forecast period 2024-2032. Request To Download Free ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by ...